There are continuous updates to this page, keep checking back to review the latest programme. Confirmed plenary speakers include:
Centre for Public Health Nutrition Research and Centre for Research into Cancer Preventions and Screening, University of Dundee, UK
Annie S. Anderson BSc PhD RD FRCP is Professor of Public Health Nutrition and Co-director of the Centre for Research into Cancer Prevention and Screening at the School of Medicine, University of Dundee. Her main research areas focus on theory based, behaviourally focused dietary and obesity (population and individual) interventions with a special interest in lifestyle related cancer. She has been an expert science member of the UK Scientific Advisory Committee on Nutrition (SACN) from 2000 to 2011 (and continues as a member of the SACN group on Maternal and Child Nutrition). She is currently Chair of the National Prevention Research Initiative (UK Medical Research Council) scientific committee. During 2013 to 2015 she was a member of the European Code Against Cancer – Physical activity, obesity, nutrition and alcohol working group for the WHO International Agency for Research on Cancer (IARC) and during 2015/16 a member of an expert working group on body fatness and cancer for the Agency. She is a policy advisor to Bowel Cancer UK and Breast Cancer Now (Scotland), a director the Scottish Cancer Foundation and co-chairs (with Professor Bob Steele) The Scottish Cancer Prevention Network.
University of Cambridge, UK
Steve Jackson FRS, FMedSci is University of Cambridge and Cancer Research UK Professor of Biology, and Head of Cancer Research UK Laboratories at the Gurdon Institute. In his research publications (h-index 117; Google Scholar), he has identified many key principles by which cells respond to and repair DNA damage. He identified many DNA repair proteins, established how they function, and helped define how their dysfunction yields cancer and other age-related diseases. Steve has received various prizes, including most recently the 2015 Gagna and van Heck Prize for Medicine, the 2016 King Faisal International Prize for Science, the 2016 AH. Heineken Prize for Medicine, and the 2017 Genome Stability Network Medal.To translate his academic work towards patient benefit, in 1997 Steve founded the drug-discovery company KuDOS Pharmaceuticals Ltd., then served as part-time Chief Scientific Officer (CSO) until and after its acquisition by AstraZeneca. Several KuDOS-generated drugs are currently in clinical trials, with the most advanced, the PARP inhibitor olaparib/LynparzaTM, now being a marketed anti-cancer drug for certain ovarian cancers in over 40 countries. In 2010, Steve founded Mission Therapeutics Ltd. (Babraham, Cambridge) to exploit recent advances in protein ubiquitylation and deubiquitylation to derive new medicines, and serves as its part-time CSO. Steve’s academic laboratory is currently further defining mechanisms of DNA repair and associated processes, with a view to identifying new therapeutic opportunities for cancer as well as various other genetic diseases.
Michigan Center for Translational Pathology, USA
Arul M. Chinnaiyan, M.D., Ph.D., is a Howard Hughes Medical Institute Investigator (HHMI) in Patient-Oriented Research, an American Cancer Society Research Professor, the S.P. Hicks Professor of Professor of Pathology and Urology and an affiliated faculty of the Bioinformatics Program at the University of Michigan Medical School. He has received a number of prestigious awards including the Pew Biomedical Scholar Award, the Amgen Outstanding Investigator Award, AACR Outstanding Investigator Award, the Benjamin Castleman Award, Paul Marks Prize for Cancer Research. Most notably, his research group was the recipient of the 2007 AACR Team Science award for the discovery of recurrent gene fusions in prostate cancer. He was elected to the Institute of Medicine of the National Academy of Sciences in 2009 and was named 2014 National Academy of Inventors Fellows. He also led the development of the popular cancer profiling bioinformatics resource called Oncomine (www.oncomine.org) (hosting over 20,000 registered users from over 30 countries and serving 16 of the 20 top oncology biopharma). In 2007, he was named the founding Director of the Michigan Center for Translational Pathology (MCTP). The Center was formed as a focused initiative to translate discoveries made in the laboratory to clinical impact in terms of novel diagnostics and therapeutics. The recent focus of the Center has been in the area of translating next generation sequencing-based approaches for use in personalized oncology. Dr. Chinnaiyan is a board-certified clinical pathologist with diverse expertise in cancer genomics, next generation sequencing (NGS), bioinformatics and biomarker development. Dr. Chinnaiyan leads a multi-disciplinary team of investigators at MCTP with expertise in pathology, genomics, proteomics, bioinformatics, cytogenetics, biostatistics, next generation sequencing and cancer biology. In addition, Dr. Chinnaiyan oversees the Center’s CLIA/CAP NGS laboratory, an extension of the Department of Pathology.
Dana-Farber Cancer Institute and Harvard Medical School, USA
|Matthew J. Ellis
Baylor College of Medicine, USA
The Netherlands Cancer Institute, Netherlands
Ton Schumacher is Principal Investigator at The Netherlands Cancer Institute. Research of his lab focuses on the development of novel technologies with which T cell responses can be measured or manipulated, and the subsequent use of these technologies to dissect tumor-specific T cell immunity in mice and men. Particular focus of his recent work is the role of cancer neo-antigens in human tumor control, and the escape mechanisms that tumor cells employ to escape such control. Schumacher is recipient of, amongst others, the Amsterdam Inventor Award (2010), Queen Wilhelmina Cancer Research Award (2014), San Salvatore Award (2014), Meyenburg Cancer Research Award (2015), and W.B. Coley Award (2016). Schumacher is also member of the Cancer Research Institute Council, professor of Immunotechnology at Leiden University, and co-founder of 3 biotechs.
Integrative Cancer Immunology Laboratory, INSERM, France
|Bin Tean Teh
National Cancer Centre and DUKE-NUS Medical School, Singapore
Dr Teh obtained his MD (1992) from the University of Queensland, Australia and his PhD (1997) from the Karolinska Institute, Sweden. Following postdoctoral works at Karolinska Institute, he joined the Van Andel Research Institute (VARI), USA in 2000 as a Senior Scientific Investigator heading the Laboratory of Cancer Genetics. From 2003, he served as the Deputy Director (Research Operations) of VARI and from 2008, Director of VARI International. He established the National Cancer Centre Singapore (NCCS)-VARI laboratory, which serves as a bridge between translational research and clinical medicine. In 2010 he received the Singapore Translational Research Investigator Award and relocated to Singapore. He served as the SingHealth Group Director for Translational Research from 2010-2012. His laboratory focuses on Asian Cancer Genomics and in the last 5 years have made seminal discoveries in the field including biliary tract cancer, urological cancer and breast tumors. He holds Adjunct Professorships at several universities worldwide including Baylor College of Medicine, USA, Nanjing University and Sun Yat-Sen University, China and the Karolinska Institute, Sweden.Dr. Teh has published extensively, with over 350 publications in high impact scientific journals. He is a past and present member of numerous editorial boards for journals including Lancet Oncology, Cancer Research, Molecular Cancer Therapeutics. Dr Teh is a recipient of the 2015 Singhealth Distinguished Researcher Award and co-recipient of the 2015 Singapore President Science Award.
Nuffield Department of Surgical Sciences, University of Oxford
Freddie Hamdy joined the University of Oxford in 2008 as Nuffield Professor of Surgery and Head of the Nuffield Department of Surgical Sciences, Professor of Urology, and Honorary Consultant Urological Surgeon, as well as Fellow of Balliol College. He trained in Surgery and Urology at Liverpool, Sheffield and Newcastle, and was founding chair of Urology, Director of the Section of Oncology and of the Division of Clinical Sciences at Sheffield. He has introduced a robot-assisted surgical programme to Oxford in 2009. He leads the Oxford NIHR BRC (Biomedical Research Centre) Surgical Innovation and Evaluation Theme, and is co-Director of the first Surgical Intervention Trials Unit in the UK. His research activities include clinical, translational and basic science programmes on the biology of urological malignancies. He is Chief Investigator of many studies including the HTA NIHR ProtecT trial on prostate cancer, the largest of its kind worldwide. He was appointed Director of the Division of Surgery and Oncology at the Oxford University Hospitals NHS Foundation Trust in November 2010. This is OUH’s largest Division with over 2000 staff, mainly based on the Churchill Hospital site, encompassing a range of surgical and oncological activities with additional specialties such as Haematology and Gastroenterology. He was elected Fellow of the Academy of Medical Sciences in 2007 and NIHR Senior Investigator in 2010.
Dr. Zietman received his undergraduate training at Oxford University in the UK and then went to medical school at the Middlesex Hospital, London University graduating in 1983. After residencies in internal medicine and clinical oncology he moved to the Massachusetts General Hospital in Boston, USA for a fellowship in radiation biology. Since joining the staff of the MGH he has authored over 200 original articles, reviews, and editorials on many aspects of GU cancer. His particular research interests are in the specific roles of active surveillance, brachytherapy, hormone therapy, and proton beam therapy in the treatment of prostate cancer. He also has a long-standing interest in the organ-sparing management of bladder cancer.
He is currently Shipley Professor of Radiation Oncology at Harvard Medical School and Program Director for the Harvard Radiation Oncology Residency. He is past-President and Chair of ASTRO and a former Chair of the NCI GU Cancer Steering Committee. Since 2011, has been the Editor-in-Chief of the International Journal of Radiation Oncology Biology Physics.
Cicely Saunders Institute, King’s College London, UK
Irene Higginson qualified in medicine from Nottingham University and has worked in wide ranging medical and university positions, including radiotherapy and oncology, in-patient and home hospice care, the Department of Health (England), and various universities. She is dual-trained in palliative medicine and public health medicine. She has developed and validated two outcome measures both freely available and used widely in palliative care: the Support Team Assessment Schedule and the Palliative care Outcome Scale (see www.pos-pal.org). She is Director of the Cicely Saunders Institute, at King’s College London, the world’s first purpose-built Institute of palliative care, integrating research, education, clinical services and support and information. Prof. Higginson is an NIHR Senior Investigator and was in 2013 awarded Fellowship of the Academy of Medical Sciences, for her contribution to the field. She has several active research programmes, leads the MSc, Diploma and Certificate in Palliative Care, supervises several PhD students and is active in teaching. Prof. Higginson has published over 450 articles in peer-reviewed journals, plus several books; her research interests and publications are in the following areas: quality of life and outcome measurements, evaluation of palliative care especially of new services and interventions, epidemiology, clinical audit, effectiveness, psychosocial care, symptom assessment, breathlessness, cachexia/anorexia, and elderly care. She plays an active role in the clinical service, including on-call, and is Director of Research and Development and Assistant Medical Director at King’s College Hospital.